SEC Comment Letter for Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Aug 21, 2025
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Aug. 21, 2025 · CIK: 0001533040 · Accession: 0000000000-25-008902
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289621
Letter
Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-3 Filed August 15, 2025 File No. 333-289621 Dear Robert Bitterman:
August 21, 2025
Robert Bitterman Chief Executive Officer Phio Pharmaceuticals Corp. 411 Swedeland Road, Suite 23-1080 King of Prussia, PA 19406
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Steven J. Abrams, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 21, 2025 Robert Bitterman Chief Executive Officer Phio Pharmaceuticals Corp. 411 Swedeland Road, Suite 23-1080 King of Prussia, PA 19406 Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-3 Filed August 15, 2025 File No. 333-289621 Dear Robert Bitterman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven J. Abrams, Esq. </TEXT> </DOCUMENT>